Search is Powered by Google
Clinical Trials / Drug Trials News

Clinical Trials: The Features And Promises Of The Brazilian Market

Main Category: Clinical Trials / Drug Trials
Also Included In: Pharma Industry / Biotech Industry
Article Date: 21 Sep 2008 - 0:00 PDT

email icon email to a friend   printer icon printer friendly   write icon view / write opinions   rate icon rate article
Current Article Ratings:

Patient / Public:not yet rated

Health Professional:not yet rated

Article Opinions: 0 posts

Frost & Sullivan will host a live briefing on Tuesday, September 23, at 3:00 pm EDT to provide industry participants an overview of a recently published study focusing on Clinical Trials Markets in Brazil.

Over the years, Brazil has increasingly raised its attractiveness for pharmaceutical clinical trials and outsourcing due to cost advantages, considerable patient pool and quality resources. Furthermore, expiring patents, and consequent increasing presence of generics drugs, and fiercely competition are compelling pharmaceutical companies to raise R&D investments and improve the speed of new drugs launching. From the challenges of pharmaceutical companies, to the need of developing new drugs for new diseases, to the increasing and aging population, these companies are setting themselves up to take advantage of promising market dynamics in Brazil.

Highlights of the briefing include analyses of: Clinical Trials market overview and profile, structure and processes, outsourcing, major challenges and trends and growth opportunities.

This briefing will benefit market participants, companies interested in participate in this market, hospitals and healthcare institutions by discussing emerging trends, market opportunities and challenges and providing a complete overview despite forward projections for the Pharmaceutical Clinical Trials Market in Brazil.

"Higher costs, competition from generics, and lack of productivity from R&D have been challenging pharmaceutical companies worldwide to better manage R&D costs and deadlines as well as improve quality of the whole drug discovery process," observes Daniela Putti, Industry Analyst at Frost & Sullivan. "To responsibly address these issues, pharmaceutical and biotech companies are seeking for more accessible and efficient clinical trial locations such as emerging countries like Brazil. Here these companies and Contract Research Organizations (CROs) may likely find promising market features and growth opportunities for clinical trials."

Frost & Sullivan will hold this live briefing at 2:00 PM CDT / 3:00 PM EDT on Tuesday, September 23, 2008, which will provide industry participants an outlook on the Brazilian Pharmaceutical Clinical Trials Market. To participate, please e-mail José María Jantus at jose.jantus@frost.com with the following information: your full name, company name, title, telephone number, e-mail address, city, state, and country. Upon receipt of the above information, a registration link will be e-mailed to you.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, partners with clients to accelerate their growth. The company's TEAM Research, Growth Consulting and Growth Team Membership empower clients to create a growth-focused culture that generates, evaluates and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 30 offices on six continents.

Frost & Sullivan




Customized Homepage Weekly Newsletters Daily News Alerts
Home About Us News Licensing Free Website Feeds Free Tools & Content Links Tell a Friend Accessibility Help / FAQ Article Submission Contact Us
Urology
ADHD Autism Diabetes

add medical news today to your facebook

medical news gadget

Add to Google


developers
website gadget code
website news code
medical news rss feed links


customize your homepage


These are the most read articles from this news category for the last 6 months:
Top Article Star
MS Damage May Be Reversed By Leukemia Drug
23 Oct 2008
Researchers in the UK found that alemtuzumab, a drug initially developed to treat leukemia, stopped the advance of multiple sclerosis (MS) in patients with early stage active relapsing-remitting multiple sclerosis (RRMS)...


Complications of Type 2 Diabetes
Complications of Type 2 Diabetes

The complications of type 2 diabetes can be devastating. Uncontrolled diabetes can lead to blindness, end stage renal disease, and circulatory problems in extremities that could require amputation of limbs. Early intervention can stop the progression of diabetes and prevent complications.

more videos are available in our health videos section.